MicroRNA-155 as a potential biomarker for breast cancer screening: a systematic review and meta-analysis

摘要

1. Clinical significance of miR-155 on diagnosing human breast cancer is discussed. 2. The meta-analysis was conducted using STATA SE 12.0. 3. The results indicate that miR-155 exhibits satisfactory performance on diagnosis for breast. Background: It is aimed to evaluate the clinical significance of miR-155 on diagnosing human breast cancer. Methods: Eligible studies were identified through multiple search strategies. The search was updated up until April 10, 2020. Fagan’s nomogram, Publication bias, meta-regression, sensitive analysis, area under the summary receiver operating characteristic (AUC), diagnostic odds ratio as well as pooled sensitivity and specificity were utilized to assess the capacity of miR-155 for diagnosis. The meta-analysis was conducted and the origin of the heterogenic property was investigated by Stata SE 12.0 and Meta-Disc software. Results: The meta-analysis contained nine articles totally with the AUC, diagnostic odds ratio, specificity, pooled sensitivity of 0.90 (95% CI, 0.88–0.93), 28.63 (95% CI, 11.22–73.04), 0.82 (95% CI, 0.72–0.89) and 0.86 (95% CI, 0.76–0.93) separately. The negative and positive likelihood ratios were 0.14 and 5. Moreover, the heterogeneity was apparent but resulted from neither sensitivity analyses nor threshold effect. Conclusion: The evidence from this study indicates that miR-155 exhibits satisfactory performance on diagnosis for breast cancer.